{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:31:29Z","timestamp":1757608289581,"version":"3.44.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.idnow.2025.105099","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:18:34Z","timestamp":1747739914000},"page":"105099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cirrhotic patients with bone and joint infections: A 10-year cohort study from a reference center"],"prefix":"10.1016","volume":"55","author":[{"given":"V.","family":"Tuloup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Doumit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Lartigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.R.","family":"Le Nail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lacasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lemaignen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2025.105099_b0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11938-019-00229-2","article-title":"Infections in cirrhosis","volume":"17","author":"Ekpanyapong","year":"2019","journal-title":"Curr Treat Options Gastro"},{"key":"10.1016\/j.idnow.2025.105099_b0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/jgh3.12877","article-title":"Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis","volume":"7","author":"Hanai","year":"2023","journal-title":"JGH Open"},{"key":"10.1016\/j.idnow.2025.105099_b0015","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40262-015-0288-9","article-title":"A prediction model of drug exposure in cirrhotic patients according to Child\u2013Pugh classification","volume":"54","author":"Steelandt","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.idnow.2025.105099_b0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40261-023-01289-0","article-title":"Dose recommendations for common drugs in patients with liver cirrhosis: a systematic literature review","volume":"43","author":"Karsten Dafonte","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.idnow.2025.105099_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2023.06.001","article-title":"Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life","volume":"31","author":"Farooq","year":"2023","journal-title":"Saudi Pharmaceutical Journal"},{"key":"10.1016\/j.idnow.2025.105099_b0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMra2203477","article-title":"Periprosthetic joint infection","volume":"388","author":"Periprosthetic","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idnow.2025.105099_b0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: An updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.idnow.2025.105099_b0040","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3390\/antibiotics12111560","article-title":"Adverse events associated with prolonged antibiotic therapy for periprosthetic joint infections\u2014a prospective study with a special focus on Rifampin","volume":"12","author":"Reinecke","year":"2023","journal-title":"Antibiotics"},{"issue":"9","key":"10.1016\/j.idnow.2025.105099_b0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01043-21","article-title":"Model-based comparative analysis of Rifampicin and Rifabutin drug-drug interaction profile","volume":"65","author":"Tuloup","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0050","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/AAC.9.3.498","article-title":"Use of clindamycin in patients with liver disease","volume":"9","author":"Hinthorn","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0055","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1016\/j.ijid.2010.06.018","article-title":"Prosthetic hip infection in patients with liver cirrhosis: an outcome analysis","volume":"14","author":"Hsieh","year":"2010","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.idnow.2025.105099_b0060","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s11999-014-3593-y","article-title":"Increased rates of periprosthetic joint infection in patients with cirrhosis undergoing total joint arthroplasty","volume":"472","author":"Jiang","year":"2014","journal-title":"Clin Orthopaed Related Res\u00ae"},{"key":"10.1016\/j.idnow.2025.105099_b0065","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1097\/MCG.0000000000001091","article-title":"Outcomes of patients with cirrhosis undergoing orthopedic procedures: an analysis of the nationwide inpatient sample","volume":"53","author":"Parikh","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.idnow.2025.105099_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.artd.2024.101516","article-title":"Liver disease increases the risk of postoperative complications in patients undergoing aseptic revision total hip and knee arthroplasty","volume":"29","author":"Kinnard","year":"2024","journal-title":"Arthroplasty Today"},{"key":"10.1016\/j.idnow.2025.105099_b0075","first-page":"15","article-title":"Anaesthesia for patients with liver disease","volume":"10","author":"Vaja","year":"2010","journal-title":"Continu Educ Anaesthesia Critical Care Pain"},{"key":"10.1016\/j.idnow.2025.105099_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102205","article-title":"Anesthesia in patients with chronic liver disease: An updated review","volume":"47","author":"Bedewy","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.idnow.2025.105099_b0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.otsr.2018.09.016","article-title":"The CRIOAc healthcare network in France: A nationwide Health Ministry program to improve the management of bone and joint infection","volume":"105","author":"Ferry","year":"2019","journal-title":"Orthop Traumatol Surg Res"},{"key":"10.1016\/j.idnow.2025.105099_b0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1302\/2046-3758.910.BJR-2019-0362.R1","article-title":"Computerized registry as a potential tool for surveillance and management of complex bone and joint infections in France: French registry of complex bone and joint infections","volume":"9","author":"Lemaignen","year":"2020","journal-title":"Bone Joint Res"},{"key":"10.1016\/j.idnow.2025.105099_b0095","unstructured":"DDI-Predictor [Internet], 2020. Home page - Quantitative prediction of drug drug interactions [cited December 16, 2020]. Available from: https:\/\/www.ddi-predictor.org\/."},{"key":"10.1016\/j.idnow.2025.105099_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.idnow.2024.104958","article-title":"Impact of pharmacist-led interventions in a multidisciplinary consultation meeting for bone and joint infection","volume":"54","author":"Royere","year":"2024","journal-title":"Infectious Diseases Now"},{"key":"10.1016\/j.idnow.2025.105099_b0105","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2146\/ajhp140031","article-title":"Antibiotic dosing in cirrhosis","volume":"71","author":"Halilovic","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.idnow.2025.105099_b0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/17512433.2016.1135733","article-title":"Variations of pharmacokinetics of drugs in patients with cirrhosis","volume":"9","author":"Pena","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.idnow.2025.105099_b0115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jac\/23.4.605","article-title":"Pharmacokinetics of amoxycillin\/clavulanic acid in serum and ascitic fluid in cirrhotic patients","volume":"23","author":"Grange","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/cpt1975184475","article-title":"Pharmacokinetics of ampicillin in cirrhosis","volume":"18","author":"Lewis","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.idnow.2025.105099_b0125","first-page":"464","article-title":"Metabolism and kinetics of ampicillin elimination in cirrhosis. Therapeutical consequences (author\u2019s transl)","volume":"56","author":"Chalas","year":"1980","journal-title":"Sem Hop"},{"key":"10.1016\/j.idnow.2025.105099_b0130","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1472-8206.1991.tb00768.x","article-title":"Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis","volume":"5","author":"Hary","year":"1991","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.idnow.2025.105099_b0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00679781","article-title":"Oral pharmacokinetics and ascitic fluid penetration of ofloxacin in cirrhosis","volume":"37","author":"Silvain","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.idnow.2025.105099_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000238934","article-title":"Oral disposition kinetics of ofloxacin in patients with compensated liver cirrhosis","volume":"38","author":"Orlando","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2025.105099_b0145","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/clpt.1989.81","article-title":"The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin","volume":"45","author":"Frost","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.idnow.2025.105099_b0150","first-page":"37","article-title":"Pharmacokinetics of ciprofloxacin in impaired liver function","volume":"9","author":"Esposito","year":"1989","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.idnow.2025.105099_b0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000238793","article-title":"Pharmacokinetics of ciprofloxacin in liver cirrhosis","volume":"36","author":"Ruhnke","year":"2009","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2025.105099_b0160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF00544237","article-title":"Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis","volume":"33","author":"Cardey","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.idnow.2025.105099_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jac\/26.suppl_B.61","article-title":"Pharmacokinetics of fluoroquinolones in hepatic failure","volume":"26","author":"Montay","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000221455","article-title":"Studies on blood serum levels of rifampicin in patients with normal and impaired liver function","volume":"19","author":"Curci","year":"2009","journal-title":"Chemotherapy"},{"key":"10.1016\/j.idnow.2025.105099_b0175","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/pharmaceutics11110578","article-title":"Development and evaluation of physiologically based pharmacokinetic drug\u2013disease models for predicting rifampicin exposure in tuberculosis and cirrhosis populations","volume":"11","author":"Rasool","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.idnow.2025.105099_b0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01070725","article-title":"The effect of cirrhosis on the disposition and elimination of clindamycin","volume":"20","author":"Avant","year":"1975","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.idnow.2025.105099_b0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1128\/AAC.7.2.153","article-title":"Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci","volume":"7","author":"Williams","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0190","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/FTD.0000000000000665","article-title":"Linezolid dosing in patients with liver cirrhosis: standard dosing risk toxicity","volume":"41","author":"Luque","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.idnow.2025.105099_b0195","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00133-20","article-title":"Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0200","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/30.3.387","article-title":"Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites","volume":"30","author":"El Touny","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0205","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1128\/AAC.26.4.493","article-title":"Effects of cirrhosis on kinetics of aztreonam","volume":"26","author":"MacLeod","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0210","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1093\/clinids\/24.Supplement_2.S184","article-title":"Pharmacokinetics of meropenem in patients with liver disease","volume":"24","author":"Thyrum","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idnow.2025.105099_b0215","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1093\/jac\/dkaa362","article-title":"Meropenem population pharmacokinetics in patients with decompensated cirrhosis and severe infections","volume":"75","author":"Bastida","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0220","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1093\/jac\/dkae310","article-title":"Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review","volume":"79","author":"Comce","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0225","first-page":"54","article-title":"Doxycycline concentration levels in bone, soft tissue and serum after intravenous infusion of doxycycline. A clinical study","author":"Gnarpe","year":"1976","journal-title":"Scand J Infect Dis Suppl"},{"key":"10.1016\/j.idnow.2025.105099_b0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/2049936113519089","article-title":"Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments","volume":"2","author":"B\u00fcdingen","year":"2014","journal-title":"Therapeut Adv Infection"},{"key":"10.1016\/j.idnow.2025.105099_b0235","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.arth.2018.12.024","article-title":"Mortality during total hip periprosthetic joint infection","volume":"34","author":"Natsuhara","year":"2019","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.idnow.2025.105099_b0240","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1097\/CORR.0000000000001838","article-title":"What are the long-term outcomes of mortality, quality of life, and hip function after prosthetic joint infection of the hip? A 10-year follow-up from Sweden","volume":"479","author":"Wildeman","year":"2021","journal-title":"Clin Orthopaed Related Res\u00ae"},{"key":"10.1016\/j.idnow.2025.105099_b0245","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.42.3.521","article-title":"Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely Ill patients during therapy","volume":"42","author":"Thomas","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0250","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.02626-15","article-title":"Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with staphylococcus aureus skin infections","volume":"60","author":"Eells","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2025.105099_b0255","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00228-013-1629-y","article-title":"Pharmacokinetic changes after placement of a transjugular intrahepatic portosystemic shunt","volume":"70","author":"De Winter","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.idnow.2025.105099_b0260","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/jhep.2001.29306","article-title":"Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts","volume":"34","author":"Chalasani","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.idnow.2025.105099_b0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/17425255.2020.1702022","article-title":"Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations","volume":"16","author":"Weersink","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.idnow.2025.105099_b0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2036.2004.02022.x","article-title":"Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status","volume":"20","author":"Zapater","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.idnow.2025.105099_b0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1472-6963-11-49","article-title":"To what extent are adverse events found in patient records reported by patients and healthcare professionals via complaints, claims and incident reports?","volume":"11","author":"Christiaans-Dingelhoff","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.idnow.2025.105099_b0280","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11999-016-5021-y","article-title":"Can surgeons adequately capture adverse events using the spinal adverse events severity system (SAVES) and OrthoSAVES?","volume":"475","author":"Chen","year":"2017","journal-title":"Clin Orthopaed Related Res\u00ae"},{"key":"10.1016\/j.idnow.2025.105099_b0285","doi-asserted-by":"crossref","first-page":"e9282","DOI":"10.2196\/publichealth.9282","article-title":"Why clinicians don\u2019t report adverse drug events: qualitative study","volume":"4","author":"Hohl","year":"2018","journal-title":"JMIR Public Health Surveillance"},{"key":"10.1016\/j.idnow.2025.105099_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.idnow.2023.104671","article-title":"Assessment of the impact of pharmacist-led intervention with antibiotics in patients with bone and joint infection","volume":"53","author":"Marque","year":"2023","journal-title":"Infectious Diseases Now"},{"key":"10.1016\/j.idnow.2025.105099_b0295","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1302\/2046-3758.111.BJR-2021-0498","article-title":"The role of multidisciplinary teams in musculoskeletal infection","volume":"11","author":"Walter","year":"2022","journal-title":"Bone Joint Res"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T02:09:00Z","timestamp":1756865340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666991925000788"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105099","relation":{},"ISSN":["2666-9919"],"issn-type":[{"type":"print","value":"2666-9919"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cirrhotic patients with bone and joint infections: A 10-year cohort study from a reference center","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105099"}}